Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Autologous induced pluripotent stem cell-derived retinal pigment epithelium
- Development stage
- Unknown
- Lead developer
- RIKEN Center for Developmental Biology
- Modality
- iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies
- Administration
- Subretinal, Ophthalmic
01
Overview
Autologous induced pluripotent stem cell-derived retinal pigment epithelium (autologous iPSC-RPE) is a regenerative therapy in which a patient’s own somatic cells are reprogrammed into induced pluripotent stem cells (iPSCs), then differentiated into retinal pigment epithelial (RPE) cells. These RPE cells are transplanted back into the patient to replace damaged or degenerated native RPE, primarily for the treatment of age-related macular degeneration (AMD), including both neovascular and geographic atrophy forms. The mechanism of action involves restoring the structure and function of the retina by re-establishing interaction between healthy RPE and photoreceptors, thereby supporting visual function. Autologous transplantation reduces immunogenicity risks compared to allogeneic approaches[1][2][5][7]. This therapy is under clinical investigation for safety and efficacy in AMD patients[8].
- Other names
- autologous iPSC-derived RPEautologous iPSC-RPEautologous induced pluripotent stem cell-derived RPE
Beyond the preview
Go deeper on Autologous induced pluripotent stem cell-derived retinal pigment epithelium.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Autologous induced pluripotent stem cell-derived retinal pigment epithelium.